Physician profile
Stephen M Dillon
NPI 1609855394
$14,024.68
in general payments reported to CMS, 2019-2025
53 companies · $29.63 in 2025
The $29.63 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,095 · 2020: $1,353 · 2021: $2,465 · 2022: $2,779 · 2023: $3,629 · 2024: $674 · 2025: $29.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,332.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,831.41 | 2019-2025 | Yeztugo |
| Viiv Healthcare Company | $2,252.17 | 2019-2024 | Apretude, Dovato, Rukobia |
| Janssen Biotech, INC. | $960.58 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $776.15 | 2019-2024 | Dificid, Pifeltro, Delstrigo |
| Abbvie INC. | $764.82 | 2020-2024 | Vraylar, Ubrelvy, Viberzi |
| Novo Nordisk INC | $432.73 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Emd Serono, INC. | $429.14 | 2019-2024 | Serostim |
| Takeda Pharmaceuticals U.S.A., INC. | $407.24 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $364.40 | 2020-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.62 | 2019-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $339.84 | 2019-2023 | Mounjaro, Jardiance, Trulicity |
| Lundbeck LLC | $327.93 | 2021-2024 | Rexulti |
| Pfizer INC. | $307.34 | 2019-2021 | |
| Astellas Pharma US INC | $276.57 | 2019-2024 | Myrbetriq, Veozah |
| Theratechnologies INC. | $272.53 | 2019-2024 | Egrifta, Trogarzo |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.